Thierry Le Chevalier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Thierry Le Chevalier has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
J.-C. Soria
Institut Gustave Roussy, 39, rue Camille Desmoulins, F-94805 Villejuif Cedex, France
2 shared publicationsJean-Charles Soria
Department of Medicine, Institut Gustave-Roussy, Villejuif, France
2 shared publicationsA. Brown
1 shared publicationB. Besse
1 shared publicationBruce E. Johnson
1 shared publicationC. Gridelli
1 shared publication
Latest Publications
- Open Access
- 1 July 2005
- Published by Elsevier in Annals of Oncology
- Vol. 16 (7) , 997-998
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy
A doublet chemotherapy, generally cisplatin or carboplatin-based, is the standard of care in the management of advanced non-small cell lung cancer (NSCLC) patients, defined as unresectable stage IIIB or stage IV disease [1]. Numerous trials have established the superiority of third generation cytotoxic agent combinations over old fashion regimens (2–4). In one of these studies published by Bonomi et al., the classical etoposide-cisplatin doublet (EC, etoposide 100 mg/m2 days 1 to 3, plus cisplatin 75 mg/m2 day 1) was compared with two different paclitaxel-cisplatin regimens (cisplatin 75 mg/m2 plus paclitaxel 135 or 250 mg/m2 as a 24-hour infusion) [3]. The median failure-free survival was 2.8 months for EC and 4.8 months in the paclitaxel arms, translating to a significant increase of median overall survival from 7.5 months to 9.9 months, respectively. Paclitaxel plus cisplatin was subsequently shown to be equivalent to the more convenient combination of paclitaxel and carboplatin (PC) which became the North-American reference regimen [5].
- 1 July 2005
- Published by Elsevier in Annals of Oncology
- Vol. 16 (7) , 997-998
Open AccessFront-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy
A doublet chemotherapy, generally cisplatin or carboplatin-based, is the standard of care in the management of advanced non-small cell lung cancer (NSCLC) patients, defined as unresectable stage IIIB or stage IV disease [1]. Numerous trials have established the superiority of third generation cytotoxic agent combinations over old fashion regimens (2–4). In one of these studies published by Bonomi et al., the classical etoposide-cisplatin doublet (EC, etoposide 100 mg/m2 days 1 to 3, plus cisplatin 75 mg/m2 day 1) was compared with two different paclitaxel-cisplatin regimens (cisplatin 75 mg/m2 plus paclitaxel 135 or 250 mg/m2 as a 24-hour infusion) [3]. The median failure-free survival was 2.8 months for EC and 4.8 months in the paclitaxel arms, translating to a significant increase of median overall survival from 7.5 months to 9.9 months, respectively. Paclitaxel plus cisplatin was subsequently shown to be equivalent to the more convenient combination of paclitaxel and carboplatin (PC) which became the North-American reference regimen [5].
- 1 June 2005
- Published by Elsevier in Seminars in Oncology
- Vol. 32 (3) , 279-283
Adjuvant Chemotherapy in Early-Stage Non-Small Cell Lung Cancer
- 1 June 2005
- Published by Elsevier in Seminars in Oncology
- Vol. 32 (3) , 279-283
Adjuvant Chemotherapy in Early-Stage Non-Small Cell Lung Cancer
- 1 March 2005
- Published by Elsevier in The Lancet Oncology
- Vol. 6 (3) , 182-184
Should adjuvant chemotherapy become standard treatment in all patients with resected non-small-cell lung cancer?
- 1 March 2005
- Published by Elsevier in The Lancet Oncology
- Vol. 6 (3) , 182-184
Should adjuvant chemotherapy become standard treatment in all patients with resected non-small-cell lung cancer?
- 1 January 2005
- Published by Elsevier in Lung Cancer
- Vol. 47 (1) , 69-80
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
- 1 January 2005
- Published by Elsevier in Lung Cancer
- Vol. 47 (1) , 69-80
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
- 1 January 2004
- Published by Elsevier in Lung Cancer
- Vol. 46, S33-S39
Adjuvant treatment of lung cancer: Current status and potential applications of new regimens
- 1 January 2004
- Published by Elsevier in Lung Cancer
- Vol. 46, S33-S39
Adjuvant treatment of lung cancer: Current status and potential applications of new regimens
- 1 January 2004
- Published by Springer Nature in American Journal of Cancer
- Vol. 3 (2) , 3-5
Adjuvant treatment
- 1 January 2004
- Published by Springer Nature in American Journal of Cancer
- Vol. 3 (2) , 3-5
Adjuvant treatment
- Open Access
- 1 October 2002
- Published by Elsevier in Annals of Oncology
- Vol. 13 (10) , 1515-1517
Is cisplatin still the best platinum compound in non-small-cell lung cancer?
Lung cancer remains the leading cause of cancer-related death in industrialized countries and is therefore a major health problem for western societies [1]. In the past, the role of chemotherapy for non-small-cell lung cancer (NSCLC) has been extensively debated and the lack of activity of most cytotoxic compounds, used as single agents or in combination, led a large part of the medical community to refute chemotherapy for patients with NSCLC. Nevertheless, anecdotical reports and occasional prospective studies suggested a potential benefit of chemotherapy in advanced NSCLC in the 1970s.
- 1 October 2002
- Published by Elsevier in Annals of Oncology
- Vol. 13 (10) , 1515-1517
Open AccessIs cisplatin still the best platinum compound in non-small-cell lung cancer?
Lung cancer remains the leading cause of cancer-related death in industrialized countries and is therefore a major health problem for western societies [1]. In the past, the role of chemotherapy for non-small-cell lung cancer (NSCLC) has been extensively debated and the lack of activity of most cytotoxic compounds, used as single agents or in combination, led a large part of the medical community to refute chemotherapy for patients with NSCLC. Nevertheless, anecdotical reports and occasional prospective studies suggested a potential benefit of chemotherapy in advanced NSCLC in the 1970s.
- 1 January 2002
- Published by Elsevier in European Journal of Cancer
- Vol. 38 (2) , 292-299
Use of chemo-radiotherapy in locally advanced non-small cell lung cancer
- 1 January 2002
- Published by Elsevier in European Journal of Cancer
- Vol. 38 (2) , 292-299
Use of chemo-radiotherapy in locally advanced non-small cell lung cancer
- Open Access
- 1 December 2001
- Published by Elsevier in Annals of Oncology
- Vol. 12 (12) , 1667-1670
Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
- 1 December 2001
- Published by Elsevier in Annals of Oncology
- Vol. 12 (12) , 1667-1670
Open AccessDo all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?